Lexeo Therapeutics (LXEO) Institutional Ownership $5.07 -0.12 (-2.31%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Lexeo Therapeutics (NASDAQ:LXEO)CurrentInstitutional OwnershipPercentage60.67%Number ofInstitutional Buyers(last 12 months)30TotalInstitutional Inflows(last 12 months)$130.00MNumber ofInstitutional Sellers(last 12 months)5TotalInstitutional Outflows(last 12 months)$26.76M Get LXEO Insider Trade Alerts Want to know when executives and insiders are buying or selling Lexeo Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data LXEO Institutional Buying and Selling by Quarter Lexeo Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails1/17/2025 SG Americas Securities LLC10,960$72K0.0%N/A0.033% 12/26/2024JPMorgan Chase & Co.10,278$93K0.0%+135.6%0.031% 12/13/2024Exome Asset Management LLC88,148$797K0.5%N/A0.267% 11/19/2024Barclays PLC50,210$454K0.0%+162.2%0.152% 11/16/2024Geode Capital Management LLC553,247$5.00M0.0%+86.5%1.673% 11/15/2024Frazier Life Sciences Management L.P.1,250,786$11.31M0.5%N/A3.783% 11/15/2024Barclays PLC50,210$454K0.0%+162.2%0.152% 11/15/2024Jane Street Group LLC35,677$323K0.0%+33.3%0.108% 11/15/2024Wellington Management Group LLP51,892$469K0.0%+134.8%0.157% 11/15/2024State Street Corp253,946$2.30M0.0%+29.4%0.768% Get the Latest News and Ratings for LXEO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Lexeo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/2024RA Capital Management L.P.546,554$4.94M0.1%-18.8%1.653% 11/15/2024Point72 Asset Management L.P.370,407$3.35M0.0%N/A1.120% 11/15/2024Polar Asset Management Partners Inc.59,800$541K0.0%-8.4%0.181% 11/15/2024Ikarian Capital LLC257,216$2.33M0.3%N/A0.778% 11/15/2024Jacobs Levy Equity Management Inc.30,346$274K0.0%N/A0.092% 11/15/2024Janus Henderson Group PLC3,763,195$34.00M0.0%+18.9%11.383% 11/14/2024PDT Partners LLC26,608$241K0.0%N/A0.080% 11/14/2024Braidwell LP728,777$6.59M0.2%-47.3%2.204% 11/14/2024Eventide Asset Management LLC1,855,986$16.78M0.3%-44.9%5.614% 11/14/2024Verition Fund Management LLC777,320$7.03M0.0%+84.5%2.351% 11/14/2024Vestal Point Capital LP850,000$7.68M0.6%+1.2%2.571% 11/14/2024MetLife Investment Management LLC14,223$129K0.0%+121.5%0.043% 11/13/2024BNP Paribas Financial Markets5,541$50K0.0%+184.2%0.017% 11/12/2024Charles Schwab Investment Management Inc.63,874$577K0.0%+107.0%0.193% 10/24/2024Novo Holdings A S1,122,581$10.15M0.5%-22.6%3.407% 10/23/2024Values First Advisors Inc.7,446$67K0.0%N/A0.023% 8/20/2024Novo Holdings A S1,450,500$23.27M1.2%-11.5%4.403% 8/1/2024Rhumbline Advisers13,357$214K0.0%+37.3%0.041% 7/26/2024Bank of New York Mellon Corp31,806$510K0.0%+12.3%0.097% 5/17/2024RA Capital Management L.P.660,938$10.36M0.1%N/A2.006% 5/17/2024Artal Group S.A.801,716$12.57M0.3%+32.9%2.434% 5/16/2024Janus Henderson Group PLC2,540,785$39.80M0.0%+9.0%7.713% 5/14/2024American International Group Inc.5,053$79K0.0%N/A0.015% 5/10/2024Vanguard Group Inc.481,755$7.55M0.0%+15.8%1.462% 5/1/2024BNP Paribas Financial Markets4,781$75K0.0%N/A0.015% 4/29/2024Cornell University126,258$1.98M30.0%N/A0.383% 2/20/2024Eventide Asset Management LLC3,002,831$40.30M0.7%N/A11.268% 2/15/2024Omega Fund Management LLC2,157,623$28.96M23.5%N/A8.096% 2/15/2024Blackstone Inc.696,110$9.34M0.0%N/A2.612% (Data available from 1/1/2016 forward) LXEO Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LXEO shares? During the previous two years, 33 institutional investors and hedge funds held shares of Lexeo Therapeutics. The most heavily invested institutionals were Janus Henderson Group PLC ($34.00M), Omega Fund Management LLC ($28.96M), Eventide Asset Management LLC ($16.78M), Artal Group S.A. ($12.57M), Frazier Life Sciences Management L.P. ($11.31M), Novo Holdings A S ($10.15M), and Blackstone Inc. ($9.34M).Learn more on LXEO's institutional investors. What percentage of Lexeo Therapeutics stock is owned by institutional investors? 60.67% of Lexeo Therapeutics stock is owned by institutional investors. Learn more on LXEO's institutional investor holdings. Which institutional investors have been buying Lexeo Therapeutics stock? Of the 30 institutional investors that purchased Lexeo Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Eventide Asset Management LLC ($3.00M), Omega Fund Management LLC ($2.16M), Frazier Life Sciences Management L.P. ($1.25M), Janus Henderson Group PLC ($809.25K), Blackstone Inc. ($696.11K), RA Capital Management L.P. ($660.94K), and Point72 Asset Management L.P. ($370.41K). How much institutional buying is happening at Lexeo Therapeutics? Institutional investors have bought a total of 10,607,107 shares in the last 24 months. This purchase volume represents approximately $130.00M in transactions. Which Lexeo Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Lexeo Therapeutics stock in the last 24 months: Eventide Asset Management LLC ($1.51M), Braidwell LP ($653.70K), Novo Holdings A S ($515.72K), RA Capital Management L.P. ($126.16K), and Polar Asset Management Partners Inc. ($5.50K). How much institutional selling is happening at Lexeo Therapeutics? Institutional investors have sold a total of 2,814,240 shares in the last 24 months. This volume of shares sold represents approximately $26.76M in transactions. Related Companies Cogent Biosciences Institutional Ownership Phibro Animal Health Institutional Ownership Relay Therapeutics Institutional Ownership Avid Bioservices Institutional Ownership Sana Biotechnology Institutional Ownership Tyra Biosciences Institutional Ownership Septerna Institutional Ownership Avadel Pharmaceuticals Institutional Ownership Immatics Institutional Ownership Cronos Group Institutional Ownership This page (NASDAQ:LXEO) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
